Clinical Application of Darifenacin Hydrobromide

  • Author:Ray Dean
  • Source:www.oceanchinachem
  • Release on :2016-05-03

Darifenacin hydrobromide is a selective muscarinic M3 receptor antagonist. M3 receptors leading detrusor contraction, the product that is by blocking the M3 receptor comes into play. For the treatment associated with urge incontinence, urgency, frequent urination symptoms of overactive bladder (OAB) patients. Darifenacin does not affect the central nervous system associated with the receptor and M1 and M2 receptors related to cardiovascular function. Compared with placebo, the product allows to reduce the number of urinary incontinence episodes per week 77%, other clinical studies have shown that this product does not damage cognitive function, and no correlation between cardiovascular disease.

Current clinical drug for the treatment of overactive bladder syndrome (OAB) is primarily anti-cholinergic receptor drugs, many of these drugs are non-selective, such as tolterodine; or selective low as oxybutynin they not only can block M3 receptors on the detrusor muscle of the bladder, but also block other receptor subtypes, such as the impact of cognitive function M1 receptors and influence myocardial function M2 receptors, and therefore in the treatment of OAB simultaneously It will have a lot of adverse reactions.

Hubei Ocean Biotech Co., Ltd. A pharmaceutical products and APIs supplier, with credible service and the honest management, we have gained good reputation at domestic and abroad market. The main cause is not only for our honesty and service, but more importantly for our quality insurance about the products we offer. That's why customers choose us, our products are rest assured to buy, it is our honesty and service solved customer’s worries, so that we could be able to extend our market and serve more people.